Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo OKs NHI Price Listing of SGLT-2 Inhibitors, New Point-Based Calculations Adopted from This Time
May 15, 2014
-
BUSINESS Santen Acquires Merck’s Eye Drugs in Japan, Key Markets
May 14, 2014
-
REGULATORY PIC/S to Discuss Japan’s Accession at Upcoming Meeting in Rome; MHLW Anticipates Formal Approval
May 14, 2014
-
BUSINESS 4 Major Wholesalers’ Average Operating Margin Tops 1% Mark, Signaling Biz Recovery
May 13, 2014
-
BUSINESS Astellas Pres. “Aware” of Rumored Marriage with Daiichi Sankyo, but Denies Any Merger at This Time
May 13, 2014
-
BUSINESS FY2013 Japan Ethical Drug Market Crosses 10 Trillion Yen Mark for 1st Time: IMS
May 12, 2014
-
BUSINESS MTPC to Push Tenelia, Canaglu to Compete in Diabetes Field
May 9, 2014
-
BUSINESS Eisai Moves to Boost Global Use of Products via Emerging Market Businesses
May 8, 2014
-
REGULATORY Pilot Program for Compassionate Access System Gets Underway with Sanofi’s Cabazitaxel
May 7, 2014
-
REGULATORY Joint Panel of Health, Science Ministries Wraps Up Talks on Ethics Code for Epidemiological, Clinical Research
May 2, 2014
-
REGULATORY Point-Based Calculations for Premiums Will Improve Predictability, Says Creator
May 1, 2014
-
BUSINESS Takeda, Teva to Commercialize Teva’s Parkinson’s Disease Treatment Rasagiline in Japan
April 30, 2014
-
ACADEMIA Chiba University to Advise Researchers to Retract Diovan Papers
April 28, 2014
-
REGULATORY MHLW Bureaucrats Think Chuikyo Will Spurn Annual Drug Price Revisions, Again
April 28, 2014
-
REGULATORY Chuikyo Subcommittee OKs Point-Based Premium Calculation Method, Adoption Scheduled in May
April 24, 2014
-
BUSINESS MTPC Names Masayuki Mitsuka as New President
April 24, 2014
-
BUSINESS Astellas Aims to Dominate SGLT-2 Inhibitor Market with Suglat
April 23, 2014
-
BUSINESS Lilly Japan Starts PIII Study of Tadalafil for DMD Treatment
April 22, 2014
-
REGULATORY MHLW Eyes 2 Year Transition for Electronic Data Submissions for New Drugs, Biosimilars
April 21, 2014
-
REGULATORY New Health Ministry Panel to Compile Report on Clinical Research Regulations by Autumn
April 18, 2014
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…